You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Express Scripts
Mallinckrodt
Harvard Business School
Johnson and Johnson

Last Updated: February 27, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 211675


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

NDA 211675 describes RINVOQ, which is a drug marketed by Abbvie Inc and is included in one NDA. It is available from one supplier. There are four patents protecting this drug. Additional details are available on the RINVOQ profile page.

The generic ingredient in RINVOQ is upadacitinib. One supplier is listed for this compound. Additional details are available on the upadacitinib profile page.
Summary for 211675
Tradename:RINVOQ
Applicant:Abbvie Inc
Ingredient:upadacitinib
Patents:4
Generic Entry Opportunity Date for 211675
Generic Entry Date for 211675*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET, EXTENDED RELEASE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 211675
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RINVOQ upadacitinib TABLET, EXTENDED RELEASE;ORAL 211675 NDA AbbVie Inc. 0074-2306 0074-2306-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0074-2306-30)
RINVOQ upadacitinib TABLET, EXTENDED RELEASE;ORAL 211675 NDA AbbVie Inc. 0074-2306 0074-2306-70 14 TABLET, EXTENDED RELEASE in 1 BOTTLE (0074-2306-70)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength15MG
Approval Date:Aug 16, 2019TE:RLD:Yes
Regulatory Exclusivity Expiration:Aug 16, 2024
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:  Start TrialPatent Expiration:Jan 15, 2031Product Flag?Substance Flag?YDelist Request?
Patented Use:TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO METHOTREXATE
Patent:  Start TrialPatent Expiration:Oct 17, 2036Product Flag?YSubstance Flag?YDelist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Moodys
Boehringer Ingelheim
Johnson and Johnson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.